Using patient-reported outcome measures in clinical trials: perspectives for and against a modular approach.
作者信息
Ng Carrie-Anne, Roydhouse Jessica, Luckett Tim, Lourenco Richard De Abreu, Mulhern Brendan
机构信息
Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW.
Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS.
出版信息
Med J Aust. 2025 Apr 21;222(7):327-330. doi: 10.5694/mja2.52629. Epub 2025 Mar 11.
Abstract
摘要
相似文献
1
Using patient-reported outcome measures in clinical trials: perspectives for and against a modular approach.在临床试验中使用患者报告的结局指标：支持和反对模块化方法的观点。
Med J Aust. 2025 Apr 21;222(7):327-330. doi: 10.5694/mja2.52629. Epub 2025 Mar 11.
2
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.针对患者报告结局问卷的特定子量表进行管理，以减轻患者负担并提高相关性：关于模块化方法的立场声明。
Qual Life Res. 2024 Apr;33(4):1075-1084. doi: 10.1007/s11136-023-03587-8. Epub 2024 Jan 24.
3
A Modular Health-Related Quality of Life Instrument for Electronic Assessment and Treatment Monitoring: Web-Based Development and Psychometric Validation of Core Thrive Items.一种用于电子评估和治疗监测的模块化健康相关生活质量工具：基于网络的核心Thrive项目开发及心理测量学验证
J Med Internet Res. 2019 Jan 25;21(1):e12075. doi: 10.2196/12075.
4
International guidance on the selection of patient-reported outcome measures in clinical trials: a review.国际临床试验中患者报告结局测量选择指南：综述。
Qual Life Res. 2021 Jan;30(1):21-40. doi: 10.1007/s11136-020-02625-z. Epub 2020 Sep 14.
5
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.评估 1 型神经纤维瘤病临床试验中丛状和皮肤神经纤维瘤相关外观问题的建议。
Clin Trials. 2024 Feb;21(1):6-17. doi: 10.1177/17407745231205577. Epub 2023 Dec 23.
6
The augment-and-modular-cage revision system for reconstruction of severe acetabular defects-two-year clinical and radiographic results.增强型模块化笼重建系统治疗严重髋臼缺损：两年临床和影像学结果。
Int Orthop. 2019 Oct;43(10):2269-2278. doi: 10.1007/s00264-018-4271-6. Epub 2018 Dec 11.
7
Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations.2005 年至 2018 年高风险医疗器械上市前批准申请中使用患者报告结局测量的关键临床试验：综述、实例及监管考虑。
Contemp Clin Trials. 2022 May;116:106757. doi: 10.1016/j.cct.2022.106757. Epub 2022 Apr 6.
8
Flexibility in patient-reported outcome and health-related quality of life measurement: The EORTC Quality of Life Group measurement strategy.患者报告结局与健康相关生活质量测量的灵活性：欧洲癌症研究与治疗组织生活质量小组测量策略
Eur J Cancer. 2025 May 2;220:115392. doi: 10.1016/j.ejca.2025.115392. Epub 2025 Mar 29.
9
Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: a randomized effectiveness trial.测试针对青少年抑郁、焦虑和行为问题的心理治疗的标准和模块化设计：一项随机有效性试验。
Arch Gen Psychiatry. 2012 Mar;69(3):274-82. doi: 10.1001/archgenpsychiatry.2011.147. Epub 2011 Nov 7.
10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
本文引用的文献
1
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.针对患者报告结局问卷的特定子量表进行管理，以减轻患者负担并提高相关性：关于模块化方法的立场声明。
Qual Life Res. 2024 Apr;33(4):1075-1084. doi: 10.1007/s11136-023-03587-8. Epub 2024 Jan 24.
2
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials.国际生活质量研究学会对美国食品和药物管理局关于癌症临床试验中核心患者报告结局的行业指南草案的评论。
Qual Life Res. 2023 Aug;32(8):2155-2163. doi: 10.1007/s11136-023-03396-z. Epub 2023 May 23.
3
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group.肿瘤学试验中使用项目库进行患者报告结局测量的建议：一个国际多学科工作组的研究结果
Lancet Oncol. 2023 Feb;24(2):e86-e95. doi: 10.1016/S1470-2045(22)00654-4.
4
Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.减少或解决患者报告结局（PRO）数据收集过程中受访者负担的关键考虑因素。
Nat Commun. 2022 Oct 12;13(1):6026. doi: 10.1038/s41467-022-33826-4.
5
Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events.时机至关重要：在描述症状性不良事件时，患者报告结局评估频率的重要性。
Clin Trials. 2022 Jun;19(3):267-273. doi: 10.1177/17407745221093935. Epub 2022 May 15.
6
Effects of patient-reported outcome assessment order.患者报告结局评估顺序的影响。
Clin Trials. 2022 Jun;19(3):307-315. doi: 10.1177/17407745211073788. Epub 2022 Jan 28.
7
The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patients' spontaneous comments written in survey margins.用于测量健康相关生活质量的扩展前列腺癌指数综合简短形式（EPIC-26）：从调查边缘处患者的自发意见中进行内容分析。
Qual Life Res. 2022 Mar;31(3):855-864. doi: 10.1007/s11136-021-02940-z. Epub 2021 Jul 21.
8
Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.采用基于欧洲癌症研究与治疗组织核心问卷（EORTC QLQ-C30）的模块化方法测量骨髓增生异常综合征患者报告的身体功能和疲劳情况。
J Patient Rep Outcomes. 2021 Jul 20;5(1):60. doi: 10.1186/s41687-021-00334-w.
9
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.澳大利亚、加拿大、英国、法国、德国、意大利和西班牙企业的健康技术评估策略与实践：一项行业指标研究。
Front Pharmacol. 2020 Dec 3;11:594549. doi: 10.3389/fphar.2020.594549. eCollection 2020.
10
Exploring the consistency of the SF-6Dv2 in a breast cancer population.探索SF-6Dv2在乳腺癌人群中的一致性。
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1017-1024. doi: 10.1080/14737167.2021.1842734. Epub 2020 Dec 1.
Zotero 插件